Valion Bio Inc (VBIO NASDAQ) stock market data APIs
$2.1389
0.15(7%)
as of September 18, 2026
Try our APIs with
free plan!
Valion Bio Inc Financial Data Overview
Price chart is built with
Anychart
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Prev. Close
2.1389
Open
2.2868
High
2.365
Low
2.1312
52 wk Range
2.05-78.75
Market Cap
1 979 K
Shares Outstanding
888 K
Revenue
-86 000
EPS
-2.17
Beta
1.792
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Valion Bio Inc data using free add-ons & libraries
Get Valion Bio Inc Fundamental Data
Valion Bio Inc Fundamental data includes:
- Net Revenue: -86 000
- EBITDA: -16 536 000
- Earnings Per Share: -198
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-14
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Valion Bio Inc News
New
Tivic Health Systems reports Q1 results
* Tivic Health Systems press release [https://seekingalpha.com/pr/20516348-valion-bio-reports-first-quarter-2026-financial-results] (VBIO [https://seekingalpha.com/symbol/VBIO]): Q1 Non-GAAP loss pe...
Valion Bio outlines end-2026 Entolimod GMP validation target as NIAID funds GI-ARS BLA-enabling work
Earnings Call Insights: Valion Bio (VBIO) Q1 2026 MANAGEMENT VIEW * “This is the first quarterly call I'm privileged to address you under our new identity, Valion Bio. Effective April 28, we com...
Vitality Biopharma Retains DelMorgan & Co. to Explore Strategic Alternatives
CLEVELAND, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”), a drug development company dedicated to unlocking the unique therapeutic p...
Vitality Biopharma Board Update
CLEVELAND, April 27, 2020 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”), a corporation dedicated to the development of ...
Get Valion Bio Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
